Abstract
There is a high rate of benzodiazepine use in the population. Benzodiazepines are used for multiple indications (anxiety, seizures, alcohol withdrawal, muscular relaxation and anesthesia). Benzodiazepines are also addictive substances and a non-negligible fraction of regular users will develop dependence. There is currently no approved pharmacotherapy for benzodiazepine use disorder treatment and optimal strategies for treatment are unclear. In this review, we aimed to summarize the findings on off-label pharmacologic therapy that have been used for BZD dependence. One classical approach is to provide a slow taper associated with counseling. Anti-epileptic drugs appear also to alleviate symptoms of withdrawal. The long-term strategies of maintenance therapy (with benzodiazepine) or of blocking therapy (with a GABA antagonist such as flumazenil) could provide some clinical benefit but have not yet been tested appropriately. Pregabalin appears promising and deserves further investigation. There is a clear need for more clinical trials in this area to improve care.
Keywords: Agonist, benzodiazepine, dependence, medication, off-label, pregabalin, replacement, treatment.
Current Pharmaceutical Design
Title:Off-Label Use of Medications for Treatment of Benzodiazepine Use Disorder
Volume: 21 Issue: 23
Author(s): Pamela Sabioni, Jonathan Bertram and Bernard Le Foll
Affiliation:
Keywords: Agonist, benzodiazepine, dependence, medication, off-label, pregabalin, replacement, treatment.
Abstract: There is a high rate of benzodiazepine use in the population. Benzodiazepines are used for multiple indications (anxiety, seizures, alcohol withdrawal, muscular relaxation and anesthesia). Benzodiazepines are also addictive substances and a non-negligible fraction of regular users will develop dependence. There is currently no approved pharmacotherapy for benzodiazepine use disorder treatment and optimal strategies for treatment are unclear. In this review, we aimed to summarize the findings on off-label pharmacologic therapy that have been used for BZD dependence. One classical approach is to provide a slow taper associated with counseling. Anti-epileptic drugs appear also to alleviate symptoms of withdrawal. The long-term strategies of maintenance therapy (with benzodiazepine) or of blocking therapy (with a GABA antagonist such as flumazenil) could provide some clinical benefit but have not yet been tested appropriately. Pregabalin appears promising and deserves further investigation. There is a clear need for more clinical trials in this area to improve care.
Export Options
About this article
Cite this article as:
Sabioni Pamela, Bertram Jonathan and Le Foll Bernard, Off-Label Use of Medications for Treatment of Benzodiazepine Use Disorder, Current Pharmaceutical Design 2015; 21 (23) . https://dx.doi.org/10.2174/1381612821666150619092039
DOI https://dx.doi.org/10.2174/1381612821666150619092039 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Arylpiperazine Derivatives Acting at 5-HT1A Receptors
Current Medicinal Chemistry Bioinformatic Application in Proteomic Research on Biomarker Discovery and Drug Target Validation
Current Bioinformatics Recent Pharmacoproteomics Studies of Warfarin in the Asia-Pacific: A New Strategy for Personalized Medicine?
Current Pharmacogenomics and Personalized Medicine Current Understanding of the Mechanisms by which Membrane-Active Peptides Permeate and Disrupt Model Lipid Membranes
Current Topics in Medicinal Chemistry Antenatal Glucocorticoids Supplementation and Central Nervous System Development
Current Drug Metabolism High Dose Immunoglobulin (IVIG) May Reduce the Incidence of Langerhans Cell Histiocytosis (LCH)-Associated Central Nervous System Involvement
CNS & Neurological Disorders - Drug Targets Major Mental Disorders and Violence: A Critical Update
Current Psychiatry Reviews Psychotherapy, Suicide and Depression, Body Dysmorphic Disorder, Aggression, an Unusual Case, and the Case for Harm Reduction in Treating Adolescent Substance Abuse
Adolescent Psychiatry The Therapeutic Potential of the Wnt Signaling Pathway in Bone Disorders
Current Molecular Pharmacology Bioorganic Compounds Produced by the Fungus Monascus and their Use in Health Sciences and Medicine
Mini-Reviews in Organic Chemistry Chemical Properties and Biological Activities of Cyclopentenediones: A Review
Mini-Reviews in Medicinal Chemistry Environmental and Pharmacological Modulation of Amphetamine- Induced 50-kHz Ultrasonic Vocalizations in Rats
Current Neuropharmacology Roles of Casein Kinase I η and δ in Gastrointestinal Cancers: Potential New Screening Markers and Drug Targets
Current Cancer Therapy Reviews Analysis Of Sexual Behavior In Adolescents
Current HIV Research The Therapeutic Value of Natural Agents to Treat miRNA Targeted Breast Cancer in African-American and Caucasian-American Women
Current Drug Targets 1,2,4-Triazoles: A Review of Synthetic Approaches and the Biological Activity
Letters in Organic Chemistry Versatility of Cancer Associated Fibroblasts: Commendable Targets for Anti-tumor Therapy
Current Drug Targets Mesenchymal Stem Cells: Key Actors in Tumor Niche
Current Stem Cell Research & Therapy Acknowledgements to Reviewers
Current Neuropharmacology Status Epilepticus in the Immature Rodent Brain Alters the Dynamics of Autophagy
Current Neurovascular Research